• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by BrainsWay Ltd. (Amendment)

    4/3/23 7:50:15 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care
    Get the next $BWAY alert in real time by email
    SC 13G/A 1 zk2329228.htm SC 13G/A


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C.  20549

    SCHEDULE 13G
    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 5)

    Brainsway Ltd.
    (Name of Issuer)

    Ordinary Shares, par value NIS 0.04 per share
     (Title of Class of Securities)

    10501L106
    (CUSIP Number)

    December 31, 2022
     (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


     
    CUSIP No. 10501L106
    13G
    Page 2 of 8 Pages
     
    1
    NAME OF REPORTING PERSONS
     
    The Phoenix Holdings Ltd.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP   (See instructions)
    (a)  ☐
    (b)  ☒
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Israel
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
    SOLE VOTING POWER
     
    ---
    6
    SHARED VOTING POWER
     
    3,768,718.69 (*)(**)
    7
    SOLE DISPOSITIVE POWER
     
    ---
    8
    SHARED DISPOSITIVE POWER
     
    3,768,718.69 (*)(**)
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    3,768,718.69 (*)(**)
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)
     
    ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
     
    11.45% (*) (***)
    12
    TYPE OF REPORTING PERSON   (See instructions)
     
    CO

    (*) The beneficial ownership of the securities reported herein is described in Item 4(a).

    (**) The amount of shares includes 1,666,922 Ordinary Shares held in 833,461 of the issuer's American depositary shares (“ADSs”). Each ADS represents two Ordinary Shares.

    (***) Based on 32,911,134 Ordinary Shares outstanding as of December 31, 2022 (as reported by the Issuer in its Form 20-F filed with the Securities and Exchange Commission on April 12, 2022).

    2


    Item 1.        (a)         Name of Issuer:

    Brainsway Ltd.

                         (b)
    Address of Issuer's Principal Executive Offices:

    19 Hartum Street, Bynet Building, 3rd Floor, Har HaHotzvim, Jerusalem, 9777518, Israel.

    Item 2.        (a)
    Name of Person Filing:

    The Phoenix Holdings Ltd.

    The securities reported herein are beneficially owned by various direct or indirect, majority or wholly-owned subsidiaries of the Phoenix Holdings Ltd. (the “Subsidiaries”).   The Subsidiaries manage their own funds and/or the funds of others, including for holders of exchange-traded notes or various insurance policies, members of pension or provident funds, unit holders of mutual funds, and portfolio management clients.  Each of the Subsidiaries operates under independent management and makes its own independent voting and investment decisions.


    (b)
    Address of Principal Business Office:

    The address of the Phoenix Holdings Ltd. is Derech Hashalom 53, Givataim, 53454, Israel. 


    (c)
    Citizenship:

    The Phoenix Holdings Ltd. - Israel


    (d)
    Title of Class of Securities:

    Ordinary Shares, par value NIS 0.04 per share


    (e)
    CUSIP Number:

    10501L106

    3

    Item 3.
    Not applicable.

    Item 4.
    Ownership:


    (a)
    Amount beneficially owned:

    See row 9 of cover page of each reporting person.

    Each of the Subsidiaries operates under independent management and makes its own independent voting and investment decisions.  Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission by either the Filing Persons or Subsidiaries that a group exists for purposes of Section 13(d) of the Securities Exchange Act of 1934 or for any other purpose, and each reporting person disclaims the existence of any such group.  In addition, each of the Filing Persons and Subsidiaries disclaims any beneficial ownership of the securities covered by this report in excess of their actual pecuniary interest therein. This Statement shall not be construed as an admission by the Filing Persons or Subsidiaries that they are the beneficial owners of any of the Ordinary Shares covered by this Statement, and each of Filing Persons and Subsidiaries disclaims beneficial ownership of any such Ordinary Shares.

    As of December 31, 2022, the securities reported herein were held as follows:

       
    Ordinary Shares
       
    Percentage of total Ordinary Shares outstanding
     
    Excellence "nostro" accounts
       
    --
         
    --
     
    Excellence provident funds
       
    --
         
    --
     
    Excellence trust funds
       
    84,687.69
         
    0.26
    %
    Excellence ETF's
       
    --
         
    --
     
    The Phoenix "nostro" accounts
       
    383,373
         
    1.16
    %
    The Phoenix pension and provident funds
       
    --
         
    --
     
    Linked insurance policies of Phoenix
       
    --
         
    --
     
    Partnership for Israeli shares (1)
       
    3,300,658
         
    10.03
    %
    Partnership for investing in shares indexes (1)
       
    --
         
    --
     
    Partnership for international shares (1)
       
    --
         
    --
     
    Halman - Aldubi Provident and Pension Funds Ltd.
       
    --
         
    --
     

    (1) All ownership rights in this partnership belong to companies that are part of Phoenix Group. The amount of ownership rights held by such companies in the partnership changes frequently according to a mechanism provided in the partnership agreement.

     
    (b)
    Percent of class:

    See row 11 of cover page of each reporting person

    4


    (c)
    Number of shares as to which such person has:


    (i)
    Sole power to vote or to direct the vote:

    See row 5 of cover page of each reporting person


    (ii)
    Shared power to vote or to direct the vote:

    See row 6 of cover page of each reporting person and note in Item 4(a) above


    (iii)
    Sole power to dispose or to direct the disposition of:

    See row 7 of cover page of each reporting person


    (iv)
    Shared power to dispose or to direct the disposition of:

    See row 8 of cover page of each reporting person and note in Item 4(a) above

    Item 5.
    Ownership of Five Percent or Less of a Class:

    Not applicable.

    Item 6.
    Ownership of More than Five Percent on Behalf of Another:

    Not applicable.

    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

    Not applicable.

    Item 8.
    Identification and Classification of Members of the Group:

    Not applicable.

    Item 9.
    Notice of Dissolution of Group:

    Not applicable.

    5

     
    Item 10.
    Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    6


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    April 2, 2023
     
       
    The Phoenix Holdings Ltd.
     
    /s/ Eli Schwartz
    By: Eli Schwartz*
    Title: Executive Vice President - Chief Financial Officer

       
    /s/ Haggai Schreiber
    By: Haggai Schreiber*
    Title: Executive Vice President - Chief Investment Officer
     
    * Signature duly authorized by resolution of the Board of Directors, notice of which is attached as Exhibit 1 to this Schedule 13G.
     
    7

     
    EXHIBIT NO.          DESCRIPTION

    Exhibit 1
    Notice of resolution of the Board of Directors of the Phoenix Holdings Ltd., dated as of December 12, 2019 (incorporated herein by reference to Exhibit 3 to the Schedule 13G filed on February 18, 2020).

      8

    Get the next $BWAY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BWAY

    DatePrice TargetRatingAnalyst
    11/16/2023Outperform → Mkt Perform
    Raymond James
    3/3/2022$15.00Buy
    Loop Capital
    11/29/2021$14.00 → $15.00Buy
    HC Wainwright & Co.
    8/12/2021$17.00 → $14.00Buy
    HC Wainwright & Co.
    7/19/2021$17.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BWAY
    SEC Filings

    See more
    • SEC Form 424B3 filed by BrainsWay Ltd.

      424B3 - Brainsway Ltd. (0001505065) (Filer)

      5/1/25 7:00:47 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by BrainsWay Ltd.

      EFFECT - Brainsway Ltd. (0001505065) (Filer)

      5/1/25 12:15:26 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • SEC Form F-3 filed by BrainsWay Ltd.

      F-3 - Brainsway Ltd. (0001505065) (Filer)

      4/22/25 4:05:48 PM ET
      $BWAY
      Medical/Dental Instruments
      Health Care

    $BWAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Brainsway downgraded by Raymond James

      Raymond James downgraded Brainsway from Outperform to Mkt Perform

      11/16/23 7:31:55 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • Loop Capital initiated coverage on BrainsWay with a new price target

      Loop Capital initiated coverage of BrainsWay with a rating of Buy and set a new price target of $15.00

      3/3/22 4:42:28 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • HC Wainwright & Co. reiterated coverage on BrainsWay with a new price target

      HC Wainwright & Co. reiterated coverage of BrainsWay with a rating of Buy and set a new price target of $15.00 from $14.00 previously

      11/29/21 6:24:14 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care

    $BWAY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BrainsWay to Showcase Deep TMS at the 2025 American Psychiatric Association Annual Meeting in Los Angeles

      BURLINGTON, Mass. and JERUSALEM, May 01, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, is proud to announce its participation at the American Psychiatric Association (APA) Annual Meeting, taking place May 17–21, 2025, in Los Angeles, California. As part of the meeting's educational programming, there will be a full day master course on Sunday, May 18, 2025, entitled: "Clinical Applications for Psychiatric Practice: Ketamine and TMS." The course will provide an in-depth look at the integration of novel treatments into clinical psychiatric practice, highlighting practical approa

      5/1/25 8:00:00 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • BrainsWay to Report First Quarter 2025 Financial Results on May 13, 2025

      BURLINGTON, Mass. and JERUSALEM, April 29, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its first quarter 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Tuesday, May 13, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time the same day to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Tuesday, May 13, 2025Time:8:30 AM Eastern TimeUnited States:1-877-300

      4/29/25 8:00:00 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • BrainsWay Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

      Achieved record quarterly sales of $11.4 million in Q4 2024, an increase of 27% compared with Q4 2023 Full year 2024 revenue increased nearly 30% YoY to $41 million Exceeded full year 2024 operating income and Adjusted EBITDA margin guidance Company expects continued strong growth in 2025, with revenue of $49 million to $51 million and further improvement in profit and profitability Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, March 11, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported fourth qua

      3/11/25 7:30:00 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care

    $BWAY
    Leadership Updates

    Live Leadership Updates

    See more
    • BrainsWay Appoints Richard A. Bermudes, M.D. as Chief Medical Officer

      BURLINGTON, Mass. and JERUSALEM, Aug. 29, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Richard A. Bermudes, M.D. as Chief Medical Officer (CMO), effective September 1, 2024. Dr. Aron Tendler, M.D., who has served as CMO since 2015, will continue to serve as a collaborator on important strategic research projects. "We are excited to have Richard join our team to lead and shape BrainsWay's clinical strategy and product roadmap. His extensive experience with TMS and brain stimulation therapies as a practicing phys

      8/29/24 7:30:00 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • Murchinson Takes Action to Replace Board of Directors of Nano Dimension at Upcoming Annual General Meeting

      Highlights Entrenchment Tactics Taken by the Board Before and Following March Special Meeting Where Shareholders Overwhelmingly Supported Murchinson's Case for Change – Including the Removal of CEO and Chairman Yoav Stern From the Board Puts Forward Proposals to Improve Company's Failed Corporate Governance by Seeking to Remove All Current Directors and Appoint Five New, Experienced and Independent Nominees Murchinson Ltd. (collectively with its affiliates and funds it advises and/or sub-advises, "Murchinson" or "we"), a significant shareholder with approximately 5.9% of the outstanding shares of Nano Dimension Ltd., a company incorporated in Israel (NASDAQ:NNDM) ("Nano Dimension" or th

      8/3/23 3:00:00 PM ET
      $BWAY
      $INSG
      $MCK
      $NNDM
      Medical/Dental Instruments
      Health Care
      Telecommunications Equipment
      Telecommunications
    • BrainsWay Announces Appointment of Ido Marom as CFO

      BURLINGTON, Mass. and JERUSALEM, May 23, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Ido Marom, an experienced senior financial leader in global industries, including medical technology, as Chief Financial Officer (CFO). Mr. Marom will succeed Scott Areglado, who will be stepping down from the Company to pursue other opportunities. "We are thrilled to welcome Ido and his extensive financial expertise to BrainsWay," stated Hadar Levy, BrainsWay's Chief Executive Officer. "He has led the financial strategy and i

      5/23/23 7:30:00 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care

    $BWAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by BrainsWay Ltd.

      SC 13G/A - Brainsway Ltd. (0001505065) (Subject)

      11/14/24 1:33:58 PM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by BrainsWay Ltd.

      SC 13G/A - Brainsway Ltd. (0001505065) (Subject)

      11/14/24 1:32:48 PM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D filed by BrainsWay Ltd.

      SC 13D - Brainsway Ltd. (0001505065) (Subject)

      11/13/24 6:09:51 PM ET
      $BWAY
      Medical/Dental Instruments
      Health Care

    $BWAY
    Financials

    Live finance-specific insights

    See more
    • BrainsWay to Report First Quarter 2025 Financial Results on May 13, 2025

      BURLINGTON, Mass. and JERUSALEM, April 29, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its first quarter 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Tuesday, May 13, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time the same day to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Tuesday, May 13, 2025Time:8:30 AM Eastern TimeUnited States:1-877-300

      4/29/25 8:00:00 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • BrainsWay Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

      Achieved record quarterly sales of $11.4 million in Q4 2024, an increase of 27% compared with Q4 2023 Full year 2024 revenue increased nearly 30% YoY to $41 million Exceeded full year 2024 operating income and Adjusted EBITDA margin guidance Company expects continued strong growth in 2025, with revenue of $49 million to $51 million and further improvement in profit and profitability Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, March 11, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported fourth qua

      3/11/25 7:30:00 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • BrainsWay to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025

      BURLINGTON, Mass. and JERUSALEM, Israel, Feb. 24, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its fourth quarter and full year 2024 financial results, as well as operational highlights, before the open of the U.S. financial markets on Tuesday, March 11, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Tuesday, March 11, 2025Time:8:30 AM Eastern TimeUnited

      2/24/25 8:00:00 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care